Phase-separated biomolecular condensates for biocatalysis
Trends Biotechnol. 2023 Nov 2:S0167-7799(23)00294-9. doi: 10.1016/j.tibtech.2023.10.003. Online ahead of print.ABSTRACTNature often uses dynamically assembling multienzymatic complexes called metabolons to achieve spatiotemporal control of complex metabolic reactions. Researchers are aiming to mimic this strategy of organizing enzymes to enhance the performance of artificial biocatalytic systems. Biomolecular condensates formed through liquid-liquid phase separation (LLPS) can serve as a powerful tool to drive controlled assembly of enzymes. Diverse enzymatic pathways have been reconstituted within catalytic condensates in...
Source: Trends in Biotechnology - November 4, 2023 Category: Biotechnology Authors: Samuel Lim Douglas S Clark Source Type: research
Phase-separated biomolecular condensates for biocatalysis
Trends Biotechnol. 2023 Nov 2:S0167-7799(23)00294-9. doi: 10.1016/j.tibtech.2023.10.003. Online ahead of print.ABSTRACTNature often uses dynamically assembling multienzymatic complexes called metabolons to achieve spatiotemporal control of complex metabolic reactions. Researchers are aiming to mimic this strategy of organizing enzymes to enhance the performance of artificial biocatalytic systems. Biomolecular condensates formed through liquid-liquid phase separation (LLPS) can serve as a powerful tool to drive controlled assembly of enzymes. Diverse enzymatic pathways have been reconstituted within catalytic condensates in...
Source: Trends in Biotechnology - November 4, 2023 Category: Biotechnology Authors: Samuel Lim Douglas S Clark Source Type: research
Cancer-on-chip models for metastasis: importance of the tumor microenvironment
Trends Biotechnol. 2023 Oct 30:S0167-7799(23)00292-5. doi: 10.1016/j.tibtech.2023.10.001. Online ahead of print.ABSTRACTCancer-on-chip (CoC) models, based on microfluidic chips harboring chambers for 3D tumor-cell culture, enable us to create a controlled tumor microenvironment (TME). CoC models are therefore increasingly used to systematically study effects of the TME on the various steps in cancer metastasis. Moreover, CoC models have great potential for developing novel cancer therapies and for predicting patient-specific response to cancer treatments. We review recent developments in CoC models, focusing on three main ...
Source: Trends in Biotechnology - November 1, 2023 Category: Biotechnology Authors: Mohammad Jouybar Charlotte M de Winde Katarina Wolf Peter Friedl Reina E Mebius Jaap M J den Toonder Source Type: research
Cancer-on-chip models for metastasis: importance of the tumor microenvironment
Trends Biotechnol. 2023 Oct 30:S0167-7799(23)00292-5. doi: 10.1016/j.tibtech.2023.10.001. Online ahead of print.ABSTRACTCancer-on-chip (CoC) models, based on microfluidic chips harboring chambers for 3D tumor-cell culture, enable us to create a controlled tumor microenvironment (TME). CoC models are therefore increasingly used to systematically study effects of the TME on the various steps in cancer metastasis. Moreover, CoC models have great potential for developing novel cancer therapies and for predicting patient-specific response to cancer treatments. We review recent developments in CoC models, focusing on three main ...
Source: Trends in Biotechnology - November 1, 2023 Category: Biotechnology Authors: Mohammad Jouybar Charlotte M de Winde Katarina Wolf Peter Friedl Reina E Mebius Jaap M J den Toonder Source Type: research
Cancer-on-chip models for metastasis: importance of the tumor microenvironment
Trends Biotechnol. 2023 Oct 30:S0167-7799(23)00292-5. doi: 10.1016/j.tibtech.2023.10.001. Online ahead of print.ABSTRACTCancer-on-chip (CoC) models, based on microfluidic chips harboring chambers for 3D tumor-cell culture, enable us to create a controlled tumor microenvironment (TME). CoC models are therefore increasingly used to systematically study effects of the TME on the various steps in cancer metastasis. Moreover, CoC models have great potential for developing novel cancer therapies and for predicting patient-specific response to cancer treatments. We review recent developments in CoC models, focusing on three main ...
Source: Trends in Biotechnology - November 1, 2023 Category: Biotechnology Authors: Mohammad Jouybar Charlotte M de Winde Katarina Wolf Peter Friedl Reina E Mebius Jaap M J den Toonder Source Type: research
Molecular engineering of insulin for recombinant expression in yeast
Trends Biotechnol. 2023 Oct 24:S0167-7799(23)00286-X. doi: 10.1016/j.tibtech.2023.09.012. Online ahead of print.ABSTRACTSince the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed...
Source: Trends in Biotechnology - October 25, 2023 Category: Biotechnology Authors: Thomas Kjeldsen Asser Sloth Andersen Franti šek Hubálek Eva Johansson Frederik Flindt Kreiner Gerd Schluckebier Peter Kurtzhals Source Type: research
Molecular engineering of insulin for recombinant expression in yeast
Trends Biotechnol. 2023 Oct 24:S0167-7799(23)00286-X. doi: 10.1016/j.tibtech.2023.09.012. Online ahead of print.ABSTRACTSince the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed...
Source: Trends in Biotechnology - October 25, 2023 Category: Biotechnology Authors: Thomas Kjeldsen Asser Sloth Andersen Franti šek Hubálek Eva Johansson Frederik Flindt Kreiner Gerd Schluckebier Peter Kurtzhals Source Type: research
Molecular engineering of insulin for recombinant expression in yeast
Trends Biotechnol. 2023 Oct 24:S0167-7799(23)00286-X. doi: 10.1016/j.tibtech.2023.09.012. Online ahead of print.ABSTRACTSince the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed...
Source: Trends in Biotechnology - October 25, 2023 Category: Biotechnology Authors: Thomas Kjeldsen Asser Sloth Andersen Franti šek Hubálek Eva Johansson Frederik Flindt Kreiner Gerd Schluckebier Peter Kurtzhals Source Type: research
Molecular engineering of insulin for recombinant expression in yeast
Trends Biotechnol. 2023 Oct 24:S0167-7799(23)00286-X. doi: 10.1016/j.tibtech.2023.09.012. Online ahead of print.ABSTRACTSince the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed...
Source: Trends in Biotechnology - October 25, 2023 Category: Biotechnology Authors: Thomas Kjeldsen Asser Sloth Andersen Franti šek Hubálek Eva Johansson Frederik Flindt Kreiner Gerd Schluckebier Peter Kurtzhals Source Type: research
Molecular engineering of insulin for recombinant expression in yeast
Trends Biotechnol. 2023 Oct 24:S0167-7799(23)00286-X. doi: 10.1016/j.tibtech.2023.09.012. Online ahead of print.ABSTRACTSince the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed...
Source: Trends in Biotechnology - October 25, 2023 Category: Biotechnology Authors: Thomas Kjeldsen Asser Sloth Andersen Franti šek Hubálek Eva Johansson Frederik Flindt Kreiner Gerd Schluckebier Peter Kurtzhals Source Type: research
Molecular engineering of insulin for recombinant expression in yeast
Trends Biotechnol. 2023 Oct 24:S0167-7799(23)00286-X. doi: 10.1016/j.tibtech.2023.09.012. Online ahead of print.ABSTRACTSince the first administration of insulin to a person with diabetes in 1922, scientific contributions from academia and industry have improved insulin therapy and access. The pharmaceutical need for insulin is now more than 40 tons annually, half of which is produced by recombinant secretory expression in Saccharomyces cerevisiae. We discuss how, in this yeast species, adaptation of insulin precursors by removable structural elements is pivotal for efficient secretory expression. The technologies reviewed...
Source: Trends in Biotechnology - October 25, 2023 Category: Biotechnology Authors: Thomas Kjeldsen Asser Sloth Andersen Franti šek Hubálek Eva Johansson Frederik Flindt Kreiner Gerd Schluckebier Peter Kurtzhals Source Type: research
Synthetic transcription factor engineering for cell and gene therapy
Trends Biotechnol. 2023 Oct 19:S0167-7799(23)00284-6. doi: 10.1016/j.tibtech.2023.09.010. Online ahead of print.ABSTRACTSynthetic transcription factors (synTFs) that control beneficial transgene expression are an important method to increase the safety and efficacy of cell and gene therapy. Reliance on synTF components from non-human sources has slowed progress in the field because of concerns about immunogenicity and inducer drug properties. Recent advances in human-derived DNA-binding domains (DBDs) and transcriptional activation domains (TADs) paired with novel control modules responsive to clinically approved small mol...
Source: Trends in Biotechnology - October 21, 2023 Category: Biotechnology Authors: Bhoomi Bhatt Pablo Garc ía-Díaz Glenna Wink Foight Source Type: research
Synthetic transcription factor engineering for cell and gene therapy
Trends Biotechnol. 2023 Oct 19:S0167-7799(23)00284-6. doi: 10.1016/j.tibtech.2023.09.010. Online ahead of print.ABSTRACTSynthetic transcription factors (synTFs) that control beneficial transgene expression are an important method to increase the safety and efficacy of cell and gene therapy. Reliance on synTF components from non-human sources has slowed progress in the field because of concerns about immunogenicity and inducer drug properties. Recent advances in human-derived DNA-binding domains (DBDs) and transcriptional activation domains (TADs) paired with novel control modules responsive to clinically approved small mol...
Source: Trends in Biotechnology - October 21, 2023 Category: Biotechnology Authors: Bhoomi Bhatt Pablo Garc ía-Díaz Glenna Wink Foight Source Type: research
Synthetic transcription factor engineering for cell and gene therapy
Trends Biotechnol. 2023 Oct 19:S0167-7799(23)00284-6. doi: 10.1016/j.tibtech.2023.09.010. Online ahead of print.ABSTRACTSynthetic transcription factors (synTFs) that control beneficial transgene expression are an important method to increase the safety and efficacy of cell and gene therapy. Reliance on synTF components from non-human sources has slowed progress in the field because of concerns about immunogenicity and inducer drug properties. Recent advances in human-derived DNA-binding domains (DBDs) and transcriptional activation domains (TADs) paired with novel control modules responsive to clinically approved small mol...
Source: Trends in Biotechnology - October 21, 2023 Category: Biotechnology Authors: Bhoomi Bhatt Pablo Garc ía-Díaz Glenna Wink Foight Source Type: research
Synthetic transcription factor engineering for cell and gene therapy
Trends Biotechnol. 2023 Oct 19:S0167-7799(23)00284-6. doi: 10.1016/j.tibtech.2023.09.010. Online ahead of print.ABSTRACTSynthetic transcription factors (synTFs) that control beneficial transgene expression are an important method to increase the safety and efficacy of cell and gene therapy. Reliance on synTF components from non-human sources has slowed progress in the field because of concerns about immunogenicity and inducer drug properties. Recent advances in human-derived DNA-binding domains (DBDs) and transcriptional activation domains (TADs) paired with novel control modules responsive to clinically approved small mol...
Source: Trends in Biotechnology - October 21, 2023 Category: Biotechnology Authors: Bhoomi Bhatt Pablo Garc ía-Díaz Glenna Wink Foight Source Type: research
